Skip to main content

SOPH · SOPHiA GENETICS SA

Track SOPH — free
$6.68 -0.79 (-10.58%) At close · Nov 19
Market Cap
$572.20M
Shares
85.66M
Volume · Nov 19 1.58M Avg daily vol (3M) 672.43K

Price & Indicators

 

Key stats

Close
$6.68
Open
$7.53
Day range
$6.67–7.65
52-week closing range
$3.89–8.92
Average volume, 30 days
690K
Short interest
1.1M · 1.3% of shares · 2.6 days
Short volume, last session
39%
Last earnings
Nov 3, 2026
Price history
Jul 2021 to Nov 2026

Up next

Mar 2, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 11
Investor event
Biopharma could reach half of revenue long term

Sophia Genetics expects biopharma to reach half of revenue long term and the United States 50% long term, while approaching $100 million of revenue, growing 25-plus percent, and targeting adjusted EBITDA profitability in the fourth quarter of next year.

4 source passages
It's my pleasure to welcome Jurgi, the founder and executive chairman of the board at Sophia Genetics. We think long term, this could be half of our revenue. The US today is maybe 20%, and this could become as well 50% of our revenue in the long term. We're reaching $100 million of revenue. We're growing 25-plus percent. We're going to be profitable from an adjusted EBITDA perspective in the fourth quarter of next year, which we've mentioned this quarter. Open the document at this passage
Nov 3
Earnings call
Revenue grew 25%; 2026 outlook at upper end

Sophia Genetics reported 25% revenue growth and expects 2026 revenue at the upper end of its $94 to $96 million guidance range. Adjusted EBITDA loss improved 31% to $6.1 million, with positive adjusted EBITDA expected in the second half of 2027.

4 source passages
We delivered 25% year-over-year revenue growth as demand for our platform continues to expand. Sophia Genetics now expects our full year 2026 revenue to be at the upper end of the previously issued guidance range of $94 to $96 million. Adjusted EBITDA loss was a loss of $6.1 million compared to the prior year loss of $8.8 million, improving 31% year-over-year. we expect to crossover to positive adjusted EBITDA in the second half of 2027. Open the document at this passage
Nov 3
Current report 6-K
Revenue rises to $24,267 thousand

SOPHiA GENETICS SA reported revenue of $24,267 thousand for the three months ended September 30, 2026, up from $19,462 thousand. Nine-month loss was $61,950 thousand, while cash and cash equivalents reached $93,652 thousand.

Read from the first part of this long document
3 source passages
Three months ended September 30, | | Nine months ended September 30, | | | --- | --- | --- | --- | --- | --- | | | Notes | | 2026 | 2025 | 2026 | 2025 | | Revenue | 5 | | 24,267 | 19,462 | 69,265 | 55,564 Loss for the period | | (20,272) | (20,021) | (61,950) | (59,820) September 30, 2026 | | December 31, 2025 | --- | --- | --- | | Cash and cash equivalents | | | 93,652 | | 70,289 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$90.97M
Trailing 12 months
Net income (TTM)
−$81.13M
Trailing 12 months
Revenue growth YoY
+24.7%
Year over year
Operating margin
-81.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$45.51M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.7%
Year over year · more shares
Price change (1Y)
+66.6%
Trailing year
Short interest
1.3%
Latest settlement · 2.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg −12%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 55%
mid-range
Momentum
relative strength
Strong
1-month return −5%
trailing
6-month return +34%
trailing
YTD return +43%
this year
Relative strength +40%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+30% holders QoQ · +31 funds added
Insider flow Accumulating
Net +$237.2K over 90 days · 50% sells
Short interest Rising
1.34% of shares out · ▲ +14.8% MoM · 2.6 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
95 holders — near 3-yr high, broad support
Squeeze score 54
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −27%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 4, 2026
Full year revenue · full year 2026 $94M – $96M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
−12% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
55% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+30% holders QoQ · +31 funds added
Insider flow Accumulating
Net +$237.2K over 90 days · 50% sells
Short interest Rising
1.34% of shares out · ▲ +14.8% MoM · 2.6 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
95 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $7 · 55% Range high $9
vs 200-day avg +10% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SOPH
SOPHiA GENETICS SA
this stock
$572.20M +43.0% — — 1.3%
VEEV
Veeva Systems Inc
$42.57B +17.8% +28.1% 43.0 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$12.74B +70.9% +28.2% 34.8 5.8%
TEM
Tempus AI, Inc.
$10.87B +0.9% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
95
% held
47.9%
Net QoQ
+4.1M sh
Top holder
GENERATION INVESTMENT MAN…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
1.1M
Days to cover
2.6d
Change
+148.0K sh
View
Short Volume
Short vol %
39%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
64
Value
$504
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
45.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$237.2K
Buyers / Sellers
2 / 2
Buyers Sellers
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
16

Sophia Genetics expects biopharma to reach half of revenue long term and the United States 50% long term, while approaching $100 million of revenue, growing 25-plus percent, and targeting adjusted EBITDA profitability in the fourth quarter of next year.

View
Proposed Sales
Value
$10.0K
Shares
1.2K
Filed
Nov 16, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View

Performance

5D 20D 120D MTD YTD
SOPH -15.0% -5.3% +33.9% -12.5% +43.0%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -9.6% +1.0% +39.5% -7.2% +38.1%
Key facts CIK 1840706 CUSIP H82027105 13F (30d) 91 filings 89 filers Visit website Investor relations